2 completed, 1 recruiting, 1 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow propagermanium: new trials by email Literature Review of propagermanium trials Research Report on propagermanium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB DMX-200, Placebo - FSGS | Phase 3 | Recruiting | Dimerix Bioscience Pty Ltd | 286 | 2022-05-30 | 2026-02-03 |
| Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 | Terminated | University of Sydney | 49 | 2022-01-07 | 2023-09-15 |
| Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Propagermanium, Placebo - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 8 | 2018-11-08 | 2022-07-29 |
| Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan Propagermanium, Placebo - Diabetic Kidney Disease | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 45 | 2018-11-06 | 2022-07-29 |
Glomerulosclerosis, Focal Segmental (2) · COVID-19 (1) · Diabetic Nephropathies (1) · Kidney Diseases (1)
Dimerix Bioscience Pty Ltd (3) · University of Sydney (1)
Australia (3) · Argentina (1) · Brazil (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Japan (1) · Malaysia (1) · Mexico (1) · New Zealand (1)
Simon Roger, MD (2) · David Fuller (1) · Meg Jardine (1) · Vivekanand Jha (1)
PMID 35224732, PMID 38724717, PMID 39438096
2023 (1)